Tony’s Takeaway: Make or break biotechs

Tony turns his attention to pivotal phase 3 trials and what mix of make or break biotechs to have in your portfolio.

Tony Locantro has been a client advisor/investment manager in the stockbroking industry since 1998. He’s focused on the small cap and emerging companies with a strong interest in identifying those in the mining, biotech and industrial sectors that offer growth potential.

He also delves into the psychology of speculation and provides regular insights on a number of social media and finance related outlets.

This week, Tony turns his attention to the boom or bust nature of pivotal phase 3 trials, looking at one to watch in Dimerix (ASX:DXB) and what mix of biotechs to include in your portfolio.

The views, information, or opinions expressed in this video are solely those of the author and do not represent the views of Stockhead.

Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this video. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.